<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parenteral antimicrobial regimens for definitive treatment of bacteremia and other invasive methicillin-resistant* &lt;em&gt;Staphylococcus aureus&lt;/em&gt; infections in children older than 28 days when antimicrobial susceptibilities are known&lt;sup&gt;[1-5]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parenteral antimicrobial regimens for definitive treatment of bacteremia and other invasive methicillin-resistant* <em>Staphylococcus aureus</em> infections in children older than 28 days when antimicrobial susceptibilities are known<sup>[1-5]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Parenteral antimicrobial regimens for definitive treatment of bacteremia and other invasive methicillin-resistant* <em>Staphylococcus aureus</em> infections in children older than 28 days when antimicrobial susceptibilities are known<sup>[1-5]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Clinical scenario</td> <td class="subtitle1" colspan="2">Antimicrobial regimens</td> </tr> <tr> <td class="subtitle2">Our preferred regimen(s)</td> <td class="subtitle2">Alternate regimen(s)</td> </tr> <tr> <td><strong>Health care-associated MRSA infection</strong></td> <td> <ul> <li>Vancomycin 15 mg/kg IV every 6 hours (maximum daily dose <span class="nowrap_whitespace">4 g/day)*<sup>¶</sup></span></li> </ul> </td> <td> <p>Consultation with an expert in infectious diseases is recommended. The preferred regimen varies with clinical features, including the site of infection and the antibiotic susceptibilities of the <span class="nowrap_whitespace">isolate<sup>Δ</sup></span>.</p> Possibilities include (only if isolate is susceptible): <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Linezolid<sup>◊</sup></span> <ul> <li>&lt;12 years: 30 mg/kg per day IV in 3 doses</li> <li>≥12 years: 600 mg twice per day IV</li> </ul> </li> <li><span class="nowrap_whitespace">Daptomycin<sup>◊</sup><sup>§</sup></span> <ul> <li>1 through 6 years: 12 mg/kg per day IV once daily</li> <li>7 through 11 years: 9 mg/kg per day IV once daily</li> <li>12 through 17 years: 7 mg/kg per day IV once daily</li> </ul> </li> <li><span class="nowrap_whitespace">Ceftaroline<sup>◊</sup></span> 15 mg/kg IV every 8 hours (maximum dose 600 mg)</li> <li>TMP-SMX 8 to 12 mg/kg: TMP 40 to 60 mg/kg, SMX per day in 4 doses</li> </ul> </td> </tr> <tr> <td colspan="3"><strong>Community-associated MRSA infection</strong></td> </tr> <tr> <td class="indent1"> <ul> <li>Sepsis</li> <li>Endocarditis</li> <li>CNS infection</li> <li>Endovascular infection</li> <li>Infection complicated by venous thrombosis</li> </ul> </td> <td> <ul> <li>Vancomycin 15 mg/kg IV every 6 hours (maximum daily dose <span class="nowrap_whitespace">4 g/day)*<sup>¶</sup></span></li> </ul> </td> <td>Consultation with an expert in infectious diseases is recommended. Alternate agents include <span class="nowrap_whitespace">ceftaroline<sup>◊</sup></span>, <span class="nowrap_whitespace">daptomycin<sup>◊</sup><sup>§</sup></span>, or <span class="nowrap_whitespace">linezolid<sup>◊</sup><sup>¥</sup>.</span></td> </tr> <tr> <td class="indent1"> <ul> <li>Pneumonia-complicating <span class="nowrap_whitespace">influenza<sup>‡</sup></span></li> </ul> </td> <td> <ul> <li>Vancomycin 15 mg/kg IV every 6 hours (maximum daily dose <span class="nowrap_whitespace">4 g/day)*<sup>¶</sup></span> <strong>plus</strong> a second anti-MRSA agent (eg, clindamycin, <span class="nowrap_whitespace">ceftaroline<sup>◊</sup></span>, <span class="nowrap_whitespace">linezolid<sup>◊</sup>)<sup>‡</sup></span> <strong>plus</strong> anti-influenza therapy</li> </ul> </td> <td> <ul> <li><span class="nowrap_whitespace">Ceftaroline<sup>◊</sup></span> 15 mg/kg IV every 8 hours (maximum dose 600 mg) <strong>plus</strong> anti-influenza therapy</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Pneumonia without concomitant influenza</li> </ul> </td> <td> <ul> <li>Clindamycin 40 mg/kg per day IV divided in 3 or 4 doses (maximum daily dose 2.7 g) (only if the isolate is susceptible)</li> </ul> </td> <td> One of the following: <ul class="decimal_heading"> <li>Vancomycin 15 mg/kg IV every 6 to 8 hours (maximum daily dose <span class="nowrap_whitespace">4 g/day)*</span></li> <li><span class="nowrap_whitespace">Linezolid<sup>◊</sup></span> (for infections caused by clindamycin-resistant isolates in children who cannot tolerate vancomycin or who have renal dysfunction) <ul> <li>&lt;12 years: 30 mg/kg per day IV in 3 doses</li> <li>≥12 years: 600 mg twice per day IV</li> </ul> </li> <li><span class="nowrap_whitespace">Ceftaroline<sup>◊</sup></span> 15 mg/kg IV every 8 hours (maximum dose 600 mg)</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Septic arthritis</li> <li>Osteomyelitis</li> </ul> </td> <td> <ul> <li>Clindamycin 40 mg/kg per day IV divided in 3 or 4 doses (maximum daily dose 2.7 g) (only if the isolate is susceptible and blood culture is negative)</li> </ul> </td> <td> One of the following: <ul class="decimal_heading"> <li>Vancomycin 15 mg/kg IV every 6 to 8 hours (maximum daily dose <span class="nowrap_whitespace">4 g/day)*</span></li> <li><span class="nowrap_whitespace">Linezolid<sup>◊</sup></span> <ul> <li>&lt;12 years: 30 mg/kg per day IV in 3 doses</li> <li>≥12 years: 600 mg twice per day IV</li> </ul> </li> <li><span class="nowrap_whitespace">Daptomycin<sup>◊</sup><sup>§</sup></span> <ul> <li>1 through 6 years: 12 mg/kg per day IV once daily</li> <li>7 through 11 years: 9 mg/kg per day IV once daily</li> <li>12 through 17 years: 7 mg/kg per day IV once daily</li> </ul> </li> <li><span class="nowrap_whitespace">Ceftaroline<sup>◊</sup></span> 15 mg/kg IV every 8 hours (maximum dose 600 mg)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant to be used in conjunction with UpToDate content on <em>S. aureus</em> infections in children. Methicillin resistance is defined by oxacillin minimum inhibitory concentration (MIC) ≥4 mcg/mL. Refer to UpToDate content for additional information about choice of antimicrobial therapy. Consultation with an expert in infectious diseases may be warranted for guidance regarding choice and duration of antimicrobial therapy.</div><div class="graphic_footnotes"><p>MRSA: methicillin-resistant <em>S. aureus</em>; IV: intravenously; TMP-SMX: trimethoprim sulfamethoxazole; CNS: central nervous system; AUC: area under the curve.</p>
<p>* Alternative dosing is suggested for clinicians/institutions who follow AUC-guided therapeutic monitoring for vancomycin for serious MRSA infections as suggested by <font class="nowrap_whitespace"><a href="https://www.idsociety.org/practice-guideline/vancomycin/" target="_blank">consensus guidelines</a><sup>[6]</sup></font>; this strategy requires input from a clinical pharmacist, who will provide recommendations for initial dosing. Refer to UpToDate content on invasive staphylococcal infections in children for details of trough-guided and AUC-guided vancomycin dosing.</p>
<p>¶ For prosthetic valve endocarditis, we add gentamicin 1 mg/kg three times per day IV and rifampin 10 mg/kg orally or IV twice per day (maximum daily dose 600 mg) for the first two weeks of treatment. For other device-related infections (eg, spinal instrumentation, pacemaker, cochlear implant, baclofen pump, prosthetic joint), we add rifampin orally or 10 mg/kg IV twice per day (maximum daily dose 600 mg) for up to two months if rifampin is tolerated and the device remains in place.</p>
<p>Δ Alternatives to vancomycin for CNS infections include <font class="nowrap_whitespace">linezolid<sup>◊</sup></font>, <font class="nowrap_whitespace">daptomycin<sup>◊</sup></font>, or <font class="nowrap_whitespace">TMP-SMX.<sup>[1]</sup></font> Daptomycin should not be used for children with concomitant pneumonia.</p>
<p>◊ Experience with these agents in children is limited. Consultation with an expert in infectious diseases may be warranted.</p>
<p>§ Daptomycin should not be used in children with concomitant pulmonary involvement. Daptomycin is active in vitro against multidrug-resistant gram-positive organisms, including <em>S. aureus</em>, but is not well studied in children. It is approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections in patients ≥1 year of age, the treatment of <em>S. aureus</em> bacteremia in children 1 through 17 years of age, and the treatment of <em>S. aureus</em> bacteremia (including right-sided endocarditis) in patients ≥18 years of age. Dosing for other indications is not well established.</p>
<p>¥ Cases of apparent failures of linezolid to treat or prevent endocarditis in patients with intravascular MRSA infection have been described. Refer to UpToDate content on treatment of invasive <em>S. aureus</em> infections in children for details.</p>
‡ For pneumonia complicating influenza, addition of a second anti-MRSA agent (eg, clindamycin, ceftaroline, linezolid) within the first 24 hours of admission may be associated with decreased mortality. Refer to UpToDate content on treatment of invasive <em>S. aureus</em> infections in children for details.</div><div class="graphic_reference">References:
<ol>
<li>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017.</li>
<li>American Academy of Pediatrics. Staphylococcus aureus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.678.</li>
<li>American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.876.</li>
<li>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</li>
<li>Cubicin (daptomycin for injection). United States Prescribing Information. Revised September, 2017. US Food and Drug Administration. Available online: <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" target="_blank">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a> (Accessed on August 1, 2018).</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
</ol></div><div id="graphicVersion">Graphic 78349 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
